Celiac disease 2015 update: new therapies.
Study Goal
The researchers aimed to evaluate the limitations of a gluten-free diet (GFD) as the sole treatment for celiac disease and explore the need for non-dietary therapies.
Results Summary
The study found that while GFD is the only current treatment for celiac disease, it often fails to fully relieve symptoms, control inflammation, or prevent long-term complications. The abstract highlights challenges with GFD adherence, lifestyle restrictions, and cost, prompting interest in alternative therapies.
Population
Individuals with celiac disease (genetically susceptible individuals with immune-mediated enteropathy triggered by gluten).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
gluten-free diet (GFD) | no change | celiac disease | genetically susceptible individuals | - | is the only available treatment | #1 |
gluten-free diet (GFD) alone | no change | symptoms | many patients | - | is not sufficient to relieve | #2 |
gluten-free diet (GFD) alone | no change | small intestinal inflammation | many patients | - | is not sufficient to control | #3 |
gluten-free diet (GFD) alone | no change | long-term complications | many patients | - | is not sufficient to prevent | #4 |
Celiac disease (CD) is a chronic, small intestinal, immune-mediated enteropathy triggered by exposure to dietary gluten in genetically susceptible individuals. Currently, lifelong adherence to a gluten-free diet (GFD) is the only available treatment. However, GFD alone is not sufficient to relieve symptoms, control small intestinal inflammation and prevent long-term complications in many patients. The GFD has its challenges including issues related to adherence, lifestyle restrictions and cost. As a result, there is growing interest in and a need for non-dietary therapies to manage this condition. In recent years, different targets in the immune-mediated cascade of CD have been identified in clinical and pre-clinical trials for potential therapies. This review will discuss the latest non-dietary therapies in CD, including endopeptidases, modulators of enterocyte tight junctions and agents involved in gluten tolerization and immunomodulation. We will also discuss the potential implications of approved therapeutics on CD clinical practice.